Alappuzha: Kerala Drugs and Pharmaceuticals Ltd (KSDP) is planning to increase its overall revenue to Rs 100 crores by adopting changes in production and marketing. KSDP MD EA Subramaniam is confident that the public sector undertaking will achieve this feat by 2024.
KSDP is planning to increase the number of medicines sold to various hospitals from 52 to 92 drugs.
The current sales, which are mainly dependent on Kerala Medical Services Corporation, will be extended to Consumerfed, Neethi Medical Stores, Supplyco, Karunya, Medibank Medical Stores and Co-operative Hospitals. KSDP MD revealed that discussions and agreements are ongoing for the same.
Meanwhile, efforts are made to ensure that medicines are also sold to private hospitals. For this purpose, KSDP has acquired a new license. Further, the production units will be completely mechanized.
In the 2020-21 financial year, Rs 120 crore in revenue was generated by KSDP. However, this was due to the increase in the sale of sanitisers during the Covid-19 pandemic.
However, as sales of sanitisers declined, the yearly turnover from medicines in 2022 went down to Rs 80 crore. Therefore, increasing production and adopting new medicines are aimed at bridging these gaps.
Currently, Jan Oushadhi shops of the central government and the governments of Telangana, Andhra Pradesh, Karnataka and Tamil Nadu are buying KSDP's medicines.
Additionally, KSDP factories have been modernized and introduced production systems as per the guidelines of the World Health Organization. So there is a high possibility of getting orders from outside the country.